The combination of IDH1 mutations and MGMT methylation status predicts survival in glioblastoma better than either IDH1 or MGMT alone

R.J. Molenaar, D. Verbaan, S. Lamba, C. Zanon, J.W.M. Jeuken, S.H.E. Boots-Sprenger, P. Wesseling, T.J.M. Hulsebos, D. Troost, A.A. van Tilborg, S. Leenstra, W.P. Vandertop, A. Bardelli, C.J.F. van Noorden, F.E. Bleeker

Research output: Contribution to journalArticleAcademicpeer-review

Original languageUndefined/Unknown
Pages (from-to)1263-1273
JournalNeuro-Oncology
Volume16
Issue number9
DOIs
Publication statusPublished - 2014

Cite this

Molenaar, R. J., Verbaan, D., Lamba, S., Zanon, C., Jeuken, J. W. M., Boots-Sprenger, S. H. E., ... Bleeker, F. E. (2014). The combination of IDH1 mutations and MGMT methylation status predicts survival in glioblastoma better than either IDH1 or MGMT alone. Neuro-Oncology, 16(9), 1263-1273. https://doi.org/10.1093/neuonc/nou005